Descompensación hiperglucémica hiperosmolar en paciente trasplantado hepático en tratamiento con acetato de megestrol

Article information

El acetato de megestrol es un progestágeno sintético con acciones e indicaciones similares a las de la progesterona y más recientemente ha sido utilizado para estimular el apetito en pacientes con caquexia asociada al cáncer y al síndrome de inmunodeficiencia humana adquirida (sida). Entre los efectos adversos descritos en relación con este fármaco están las anomalías del metabolismo hidrocarbonado. Presentamos el caso de un paciente que desarrolló un síndrome de descompensación hiperglucémica hiperosmolar no cetósica tras la introducción de acetato de megestrol como estimulante del apetito.

Palabras clave:

Acetato de megestrol

Hiperglucemia

Diabetes mellitus

Descompensación hiperglucémica hiperosmolar no cetósica

Megestrol acetate is a synthetic, orally active progestational agent with actions and indications similar to those of progesterone. This agent has been used as an appetite stimulant in patients with cachexia associated with cancer and acquired immunodeficiency syndrome (AIDS). One of the adverse effects that has been described in relation with this drug is abnormal glucose metabolism. We present a case of hyperglycemic hyperosmolar nonketotic syndrome in a patient who received this agent as an appetite stimulant.

Key words:

Megestrol acetate

Hyperglycemia

Diabetes mellitus

Hyperosmolar hyperglycemic nonketotic syndrome

Full text is only aviable in PDF

Bibliografía

[1.]

J. Feliu, M. González-Baron, A. Berrocal, A. Artal, A. Ordóñez, P. Garrido, et al.

Usefulness of megestrol acetate in cancer cachexia and anorexia.

Am J Clin Oncol, 15 (1992), pp. 432-440

[2.]

C. Cuerda, A. Zugasti, I. Bretón, M. Camblor, P. Miralles, P. García.

Treatment with nandrolone decanoate and megestrol acetate in HIV-infected men.

Nutr Clin Pract, 20 (2005), pp. 93-97

Medline

[3.]

N.S. Tchekmedyian, N. Tait, J. Abrams, J. Aisner.

High dose megestrol acetate in the treatment of advanced breast cancer.

Semin Oncol, 15 (1988), pp. 44-49

Medline

[4.]

K. Podratz, P. O’Brien, G. Malkasian, D. Decker, J. Jefferies, J. Edmonson.

Effects of progestational agents in treatment of endometrial carcinoma.

Obstet Gynecol, 66 (1985), pp. 106-110

Medline

[5.]

C.L. Loprinzi, N.M. Ellison, D.J. Schaid, J.E. Krook, L.M. Athmann, A.M. Dose, et al.

Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia.

J Natl Cancer Inst, 82 (1990), pp. 1127-1132

Medline

[6.]

J.G. Timpone, D.J. Wright, N. Li, M.J. Ergorin, M.E. Enama, J. Mayers, et al.

The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative.

AIDS Res Hum Retoviruses, 13 (1997), pp. 305-315

[7.]

C.L. Loprinzi, D.J. Schaid, A.M. Dose, N.L. Burnham, M.D. Jensen.

Body composition changes in patients who gain weight while receiving megestrol acetate.

J Clin Oncol, 11 (1993), pp. 152-154

http://dx.doi.org/10.1200/jco.1993.11.1.152 | Medline

[8.]

A.P. Panwalker.

Hyperglycemia induced by megestrol acetate.

Ann Intern Med, 116 (1992), pp. 878

Medline

[9.]

P.G. Rose.

Hyperglycemia secondary to megestrol acetate for endometrial neoplasia.

Gynecol Oncol, 61 (1996), pp. 139-141

http://dx.doi.org/10.1006/gyno.1996.0112 | Medline

[10.]

P. Jain, L.S. Girardi, L. Sherman, M. Berelowicz, L.G. Smith.

Insulin resistance and development of diabetes mellitus associated with megestrol acetate therapy.

Postgrad Med J, 72 (1996), pp. 365-367

Medline

[11.]

L. González Del-Valle, A. Herrero Ambrosio, P. Martínez Hernández, B. García Díaz, E. Jiménez Caballero.

Hyperglycemia induced by megestrol acetate in a patient with AIDS.

Ann Pharmacother, 30 (1996), pp. 1113-1114

Medline

[12.]

J.M. Kilby, P.B. Taberaux.

Severe hyperglycemia in an HIV clinic: preexisting versus drug-associated diabetes mellitus.

J Acquir Immune Defic Syndr Hum Retrovirol, 17 (1998), pp. 46-50

Medline

[13.]

S. Alyaarubi, M. Ramsay, C. Rodd.

Megestrol acetate promotes euglycemia and appetite in a child with persistent hyperinsulinemic hypoglycemia of infancy.

Acta Paediatr, 93 (2004), pp. 422-423

Medline

[14.]

M.T. Sutter-Dub, B. Dazey, E. Hamden, M.T. Vergnaud.

Progesterone and insulin resistance: studies of progesterone action on glucose transport, lipogenesis and lipolysis in isolated fat cell of the female rat.

J Endocrinol, 88 (1981), pp. 455-462

Medline

[15.]

A.W. Hamburger, H. Parnes, G.B. Gordon, L.M. Shantz, K.A. O’Donnell, J. Aisner.

Megestrol acetate induced differenciation of 3T3-L1 adipocytes in vitro.

Semin Oncol, 15 (1988), pp. 76-77

Medline